McKesson reported third-quarter earnings per share of $9.34, surpassing the consensus estimate of $9.19 by $0.15, while revenue reached $106.16 billion versus the expected $105.98 billion. This performance represents an 11.4% year-over-year sales increase and reflects expansion in both gross profit and operating income. Trading volume for the day topped 586,810 shares as investors responded positively to the stronger-than-forecast results and the company’s ability to convert specialty-pharma momentum into tangible top-line growth.

Management raised full-year adjusted EPS guidance to a range of 38.80–39.20, up from prior targets, signaling confidence in continued growth in oncology and specialty drug distribution services. The upward revision is grounded in ongoing investments in biopharma logistics and technology platforms designed to streamline supply-chain operations for hospital and retail pharmacy customers. Executives cited stable margin trends and pipeline opportunities in high-value, non-acute care segments as key drivers underpinning the revised outlook.

The board declared a quarterly dividend of $0.82 per share, translating to an annualized payout of $3.28 and a dividend-payout ratio of 9.43%. The dividend will be paid to shareholders of record on March 2, with payment on April 1. McKesson’s low payout ratio provides room for future increases, while its cash-flow profile—despite a noted decline in operating cash flow versus the prior year—remains sufficient to support ongoing capital allocation priorities, including debt reduction and selective share repurchases.

Analyst actions were mixed: UBS and Morgan Stanley lifted price targets and maintained bullish stances, while several firms retained neutral or hold ratings despite acknowledging the earnings beat. Two analysts rate the shares as Strong Buy, eleven as Buy and four as Hold, equating to an average Moderate Buy consensus. On the institutional front, Sequent Planning LLC increased its stake by 10.6% in the fourth quarter, while TD Private Client Wealth LLC added 19.2% more shares. Overall, hedge funds and other institutions now control approximately 85.1% of outstanding shares, highlighting broad portfolio allocation to McKesson within healthcare services strategies.